NCT04458272 - A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

March 10, 2023

Study Completion Date

August 31, 2026

Conditions

WHO Grade II Glioma

Interventions

DRUG

DS-1001b

250 mg, twice daily, continuous oral administration

Trial Locations (11)

Nagoya University Hospital, Nagoya

Kitasato University Hospital, Sagamihara

Tohoku University Hospital, Sendai

Saitama Medical University International Medical Center, Hidaka

Hiroshima University Hospital, Hiroshima

Kumamoto University Hospital, Kumamoto

Kyoto University Hospital, Kyoto

National Hospital Organization Osaka National Hospital, Osaka

Kyorin University Hospital, Tokyo

National Cancer Center Hospital, Tokyo

Tokyo Women's Medical University Hospital, Tokyo